Selected article for: "activation process and acute respiratory infection"
Author: Brambilla, Marta; Canzano, Paola; Becchetti, Alessia; Tremoli, Elena; Camera, Marina
Title: Alterations in platelets during SARS-CoV-2 infection
  • Cord-id: 0riolo2v
  • Document date: 2021_8_13
    • ID: 0riolo2v
    Snippet: Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet–platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets a
    Document: Coronavirus disease 2019 (COVID-19) is a pandemic syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 infection induces a process of inflammation and thrombosis supported by an altered platelet activation state. This platelet activation is peculiar being characterized by the formation of platelet-leukocytes rather than platelet–platelet aggregates and by an increased procoagulant potential supported by elevated levels of TF positive platelets and microvesicles. Therapeutic strategies targeting, beyond systemic inflammation (i.e. with tocilizumab, an anti interleukin-6 receptor), this state of platelet activation might therefore be beneficial. Among the antithrombotic drugs proposed as candidates to treat patients with SARS-CoV-2 infection, antiplatelet drugs, such as aspirin are showing promising results.

    Search related documents:
    Co phrase search for related documents
    • absolute reduction and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activated platelet and acute phase: 1
    • activated platelet and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • activated platelet and adaptive immune response: 1
    • activation prone and acute respiratory syndrome: 1
    • activation prone and adaptive immune response: 1
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive immune response develop: 1, 2
    • acute respiratory syndrome and adenovirus human immunodeficiency virus: 1, 2, 3
    • acute respiratory syndrome and lmwh thromboprophylaxis: 1, 2